
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Prospective Analysis of Spinal Epidural Abscess
Francis Farhadi
Spinal Epidural Abscess
This is a prospective study involving all patients treated at the University of Kentucky
for spinal epidural abscess over a 2-year period. Based on ongoing referrals of patients
with SEA, we expect that 200 patients will be enrolled during this time window. We
propose to study all available clinica1 expand
This is a prospective study involving all patients treated at the University of Kentucky for spinal epidural abscess over a 2-year period. Based on ongoing referrals of patients with SEA, we expect that 200 patients will be enrolled during this time window. We propose to study all available clinical, pathological, radiological, and socioeconomic data of patients diagnosed with a spinal infection with or without a history of drug abuse over this study period. All patients' charts will be prospectively reviewed starting at the time of presentation for a period of 1 year. Type: Observational Start Date: Jul 2022 |
|
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Philip Kern
Pre-diabetes
Obesity
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in
improved glucose metabolism, including a reversal of prediabetes in obese,
insulin-resistant human research participants, and this is further improved by
combination therapy with tadalafil. The investigator will1 expand
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo. Type: Interventional Start Date: Dec 2021 |
|
Healthy Recovery After Trauma Study
Christal L Badour
Stress Disorders, Post-Traumatic
Shame
Guilt
Sexual Assault and Rape
Mental contamination-an internal experience of dirtiness evoked in the absence of
physical contact with an external source-has been linked to the development and
maintenance of posttraumatic stress disorder (PTSD) following exposure to sexual abuse or
assault (Adams et al., 2014; Badour et al., 2011 expand
Mental contamination-an internal experience of dirtiness evoked in the absence of physical contact with an external source-has been linked to the development and maintenance of posttraumatic stress disorder (PTSD) following exposure to sexual abuse or assault (Adams et al., 2014; Badour et al., 2013; Brake et al., 2017). Mental contamination has been associated with greater PTSD severity (Rachman et al., 2015) and higher elevations in specific PTSD symptom clusters (particularly those of intrusive reexperiencing, negative cognitions/mood, and arousal/reactivity; Brake et al., 2019; Fergus & Bardeen, 2016). Additionally, trauma-related mental contamination has been linked to a number of negative posttraumatic emotions such as shame, guilt, disgust, and anger (Fairbrother & Rachman, 2004; Radomsky & Elliott, 2009) Despite clear and consistent links between mental contamination and problematic posttraumatic outcomes following sexual trauma, there is a dearth of research investigating how existing or promising new interventions for PTSD impact mental contamination. Cognitive Processing Therapy (CPT) is an efficacious and effective 12-session manualized cognitive-behavioral intervention for PTSD that is considered a gold-standard empirically-supported treatment for PTSD that is recommended by the American Psychological Association (APA, 2017). In addition to PTSD symptom improvement, CPT has also demonstrated benefit for improving feelings of shame and guilt, which are often seen among individuals with trauma-related mental contamination (Nishith et al., 2005; Resick et al., 2002, 2008). Cognitive reappraisal, a primary technique employed in CPT, involves challenging one's view of an emotionally-eliciting situation to alter its emotional impact (Gross & John, 2003). However, some investigators have suggested that cognitive reappraisal may be less effective in targeting moral emotions such as shame, guilt, and self-disgust that are based on an individual's standards and virtues (Finlay, 2015). Self-compassion (SC; i.e., self-directed care and kindness; forgiveness; and feelings of common humanity; Neff, 2003) has been proposed as an alternative method for addressing trauma-related shame and preliminary evidence suggests a 6-session self-compassion intervention may have benefit for reducing both PTSD symptoms and trauma-related shame (Au et al., 2017). Given the centrality of shame, guilt, and self-disgust to the experience of mental contamination, and the fact that mental contamination often arises in response to experiences involving moral violation or betrayal (Millar et al., 2016; Rachman, 2010), a SC intervention for PTSD may also offer promise as a standalone or adjunctive intervention for reducing trauma-related mental contamination. A test of these interventions for their impact on reducing trauma-related mental contamination is needed. The current study will use Single Case Experimental Design to isolate and evaluate the effects of CPT and SC in reducing both PTSD symptoms and trauma-related mental contamination among individuals with PTSD resulting from sexual trauma. Aims: 1) explore whether participants demonstrate reductions in mental contamination and PTSD symptoms in response to 12-sessions of CPT or 6-sessions of a SC intervention; 2) evaluate whether presentation of either treatment first yields differences in symptom reduction for PTSD and/or mental contamination symptoms; 3) evaluate whether the addition of the alternative module will enhance reductions in PTSD symptoms and mental contamination; 4) evaluate if such reductions are maintained during follow-up. Visual inspection analysis and statistical methods will be used to draw conclusions regarding the effects of the interventions on PTSD symptoms and mental contamination. Type: Interventional Start Date: Sep 2020 |
|
Thoracic-Lumbar Arthrodesis- Implanet Jazz
Francis Farhadi
Spondylolisthesis
Spinal Stenosis
Degenerative Disease
Establish a data repository of patients who have undergone single, two-, or three-level
lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System. expand
Establish a data repository of patients who have undergone single, two-, or three-level lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System. Type: Observational [Patient Registry] Start Date: Feb 2022 |
|
Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI
Sam Tyagi
Descending Aortic Dissection
Postoperative Pain
Thoracoabdominal Aortic Aneurysm
The objective of this study is to identify the opioid-sparing effects, and pain-reduction
potential of low dose, sub-dissociative ketamine on patients undergoing thoracic
endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion
(NCI). expand
The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI). Type: Interventional Start Date: Dec 2020 |
|
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Nicole Hamblett
Cystic Fibrosis
The REACH study is for people with CF who do not take cystic fibrosis transmembrane
conductance regulator (CFTR) modulators. The goal of the REACH study is to collect
research data, including health data and specimens, from people with CF who do not take
CFTR modulators. This data may be used to in1 expand
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study. Type: Observational Start Date: Sep 2024 |
|
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral1
Craig van Horne, MD, PhD
Parkinson's Disease
The investigators propose a Phase I single surgical-center, double-blinded randomized
parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT)
delivery into the NBM or the alternate target also affecting cognition in this
population, the substantia nigra (SN), to address1 expand
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery. Type: Interventional Start Date: Jul 2025 |
|
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
University of Nebraska
Rectal Cancer
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of
investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course
chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal
adenocarcinoma (RAC) patients. expand
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients. Type: Interventional Start Date: Aug 2022 |
|
PT150 Drug for Use in Alcohol Use Disorder
Pop Test Oncology LLC
Alcohol Use Disorder
The goal of this study is to learn if PT150 can reduce the behavioral and physical
effects of stress, alcohol, and alcohol use in people with alcohol use disorder. expand
The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder. Type: Interventional Start Date: Feb 2025 |